The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma

References

• Fish EN, Platanias LC. Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. Mol Cancer Res. 2014;12(12):1691–1703.
   PubMed Web of Science ®Google Scholar
• Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34–55.
   PubMed Web of Science ®Google Scholar
• Roferon-A [package insert]. Nutley, NJ: Hoffmann-La Roche Inc; 2008.
   Google Scholar
• Intron-A(R) [package insert]. Whitehouse Station, NJ: Merk Sharp & Dohme Corp; 2011.
   Google Scholar
• Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000;68(5):556–567.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Heathcote JE, Martin N, et al. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin Investig Drugs. 2001;10(12):2201–2213.
   PubMed Web of Science ®Google Scholar
• Sylatron(TM) [package insert]. Whitehouse Station, NJ: Merk Sharp & Dohme Corp; 2011.
   Google Scholar
• Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13(11):2776–2783.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–2458.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Dreno B, de la Salmonière P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351(9120):1905–1910.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366(9492):1189–1196.
   PubMed Web of Science ®Google Scholar
• Hansson J, Aamdal S, Bastholt L, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol. 2011;12(2):144–152.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117–126.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Jouary T, Dréno B, et al. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer. 2013;49(1):166–174.
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Gutzmer R, Hauschild A, et al. Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Ann Oncol. 2016;27(8):1625–1632.
   PubMed Web of Science ®Google Scholar
• Payne MJ, Argyropoulou K, Lorigan P, et al. Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol. 2014;32(3):185–190.
   PubMed Web of Science ®Google Scholar
• Mohr P, Hauschild A, Trefzer U, et al. Intermittent high-dose intravenous interferon alfa-2b for adjuvant treatment of stage III Melanoma: final analysis of a randomized phase III Dermatologic Cooperative Oncology Group Trial. J Clin Oncol. 2015;33(34):4077–4084.
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Lee SJ, Yip W, et al. Phase III randomized study of 4 weeks of high-dose interferon-alpha-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017;35(8):885–892.
   PubMed Web of Science ®Google Scholar
• Mocellin, S., Lens MB, Pasquali S, et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. 2013;6:CD008955.
   PubMed Web of Science ®Google Scholar
• Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635–3648.
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012;48(2):218–225.
   PubMed Web of Science ®Google Scholar
• Wheatley K, Ives N, Eggermont AM, et al. Interferon-alpha as adjuvant therapy for melanoma: an individual patient meta-analysis of randomized trials. J Clin Oncol. 2007;25:abstract 8526.
   Google Scholar
• Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998;16(4):1425–1429.
   PubMed Web of Science ®Google Scholar
• Roferon-A 3 million international units (IU) solution for injection in pre-filled syringe. [cited 2017 Jan 11]. Available from: http://www.medicines.org.uk/emc/medicine/1730/SPC/Roferon-A%20Pre-Filled%20Syringe/.
   Google Scholar
• Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493–501.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002;20(17):3703–3718.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008;112(5):982–994.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370–2380.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob -J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–1855.
   PubMed Web of Science ®Google Scholar
• Yervoy(R) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2016.
   Google Scholar
• Lin R, Yellin. M, Lowy I, et al. An alalysis of the effectiveness of specific guidelines for management of ipilimumab-mediated diarrhea/colitis: prevention of intestinal perforation and/or colectomy. J Clin Oncol. 2008;26(suppl):abstract 9063.
   Google Scholar
• Ascierto PA, del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18:611–622.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni. V, Gonzalez R, et al., Overall survival results from a phase III trial of nivolumab combined with ipilimumab in treatment-naive patients with advanced melanoma (CheckMate-067) ; Press conference. In: Proceedings from the 2017 American Association for Cancer Research Annual Meeting; April 2–5, 2017; Washington DC. Abstract CT075.
   Google Scholar